News25/Ratings7
Price$0.82-0.04 (-4.60%)
05:30 PM07:45 PM
News · 26 weeks380%
2026-03-012026-08-23
Mix1690d
- SEC Filings7(44%)
- Other5(31%)
- Insider3(19%)
- Leadership1(6%)
Latest news
25 items- PRCelularity Provides Update Regarding Nasdaq Listing ComplianceFLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company") today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commiss
- SECCelularity Inc. filed SEC Form 8-K: Leadership Update8-K - Celularity Inc (0001752828) (Filer)
- SECCelularity Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Celularity Inc (0001752828) (Filer)
- SECSEC Form 25-NSE filed by Celularity Inc.25-NSE - Celularity Inc (0001752828) (Subject)
- SECCelularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits8-K - Celularity Inc (0001752828) (Filer)
- SECCelularity Inc. filed SEC Form 8-K: Leadership Update8-K - Celularity Inc (0001752828) (Filer)
- INSIDERSEC Form 4 filed by Large owner Philip & Daniele Barach Family Trust4 - Celularity Inc (0001752828) (Issuer)
- INSIDERSEC Form 4 filed by Large owner Barach Philip Alan4 - Celularity Inc (0001752828) (Issuer)
- INSIDERSEC Form 4 filed by Large owner Barach Daniele Wolf4 - Celularity Inc (0001752828) (Issuer)
- SECCelularity Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Celularity Inc (0001752828) (Filer)
- PRCelularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell TherapiesFLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, and Fountain Life Management, LLC ("Fountain Life"), a leading healthy longevity company delivering a next-generation preventive health model through advanced diagnostics, restorative therapeutics, and AI-driven health intelligence, today announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State of Florida under recently enacted legislation supporting responsi
- SECCelularity Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Celularity Inc (0001752828) (Filer)
- PRCelularity Releases CEO Letter to ShareholdersFLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below. Dear Fellow Shareholders, I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context of evolving clinical and regulatory progress.
- PRCelularity Appoints Rick Gonzalez as Chief Commercial OfficerFLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company's broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman, Chief Executive Officer and Founder. "Rick's appointment comes at an important time for Celularity as we conti
- PRCelularity Receives Nasdaq Notice Regarding Form 10-QFLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter on May 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company's delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission. The Nasdaq notification lette
- SECCelularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Celularity Inc (0001752828) (Filer)
- SECSEC Form NT 10-Q filed by Celularity Inc.NT 10-Q - Celularity Inc (0001752828) (Filer)
- PRCelularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic TransformationFLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that it has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission. As previously disclosed, on April 16, 2026, the Company received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq's continued listi
- SECSEC Form 10-K filed by Celularity Inc.10-K - Celularity Inc (0001752828) (Filer)
- PRNEXGEL Appoints Ian Blackman as Chief Financial OfficerVeteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer. Mr. Blackman will help to advance the closing of the definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc., ("Celularity")
- INSIDERSEC Form 3 filed by new insider Barach Philip Alan3 - Celularity Inc (0001752828) (Issuer)
- INSIDERSEC Form 3 filed by new insider Barach Daniele Wolf3 - Celularity Inc (0001752828) (Issuer)
- INSIDERSEC Form 3 filed by new insider Philip & Daniele Barach Family Trust3 - Celularity Inc (0001752828) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Celularity Inc.SCHEDULE 13D/A - Celularity Inc (0001752828) (Subject)
- SECCelularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Leadership Update, Other Events, Financial Statements and Exhibits8-K - Celularity Inc (0001752828) (Filer)
CELU FAQ
6 questionsWhere does CELU stock trade?
Celularity Inc. (CELU) is listed on NASDAQ.What sector and industry is CELU in?
Celularity Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Celularity Inc. go public?
Celularity Inc. (CELU) completed its IPO in 2019.What are analysts saying about CELU?
Celularity Inc. has had 7 recent analyst actions on file. The most recent action was from Morgan Stanley: Underweight with a $100.00 price target on 2023-01-30.What companies are similar to CELU?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CELU side-by-side with any of them on Quantisnow.How can I track CELU on Quantisnow?
Quantisnow aggregates Celularity Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CELU to receive live email and push alerts on every new disclosure.